Human CD3 transgenic mice: Preclinical testing of antibodies promoting immune tolerance

Science Translational Medicine

Volumn 3, Issue 68, 2011, Pages

  Kuhn, Chantal ^a,b   You, Sylvaine ^a,b   Valette, Fabrice ^a,b   Hale, Geoff ^c,d   Van Endert, Peter ^a,b   Bach, Jean François ^a,b   Waldmann, Herman ^c   Chatenoud, Lucienne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Merck/Millipore   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCLONAL ANTIBODY 2C11; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY YTH12.5; OTELIXIZUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENIC MODULATION; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MITOGENICITY; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 79551715405     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001830     Document Type: Article

References (44)

1. M. Feldmann, Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364-371 (2002).
2. J. F. Colombel, W. J. Sandborn, W. Reinisch, G. J. Mantzaris, A. Kornbluth, D. Rachmilewitz, S. Lichtiger, G. D'Haens, R. H. Diamond, D. L. Broussard, K. L. Tang, C. J. van der Woude, P. Rutgeerts; SONIC Study Group, Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
3. CAMMS223 Trial Investigators, A. J. Coles, D. A. Compston, K. W. Selmaj, S. L. Lake, S. Moran, D. H. Margolin, K. Norris, P. K. Tandon, Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
4. C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. A. Panzara, A. W. Sandrock; AFFIRM Investigators, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
5. S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C. H. Smith; HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
6. I. Sanz, F. E. Lee; Medscape, B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 326-337 (2010).
7. J. G. Gray, A. P. Monaco, M. L. Wood, P. S. Russell, Studies on heterologous anti-lymphocyte serum in mice. I. In vitro and in vivo properties. J. Immunol. 96, 217-228 (1966).
8. N. L. Gutstein, W. E. Seaman, J. H. Scott, D. Wofsy, Induction of immune tolerance by administration of monoclonal antibody to L3T4. J. Immunol. 137, 1127-1132 (1986).
9. R. J. Benjamin, H. Waldmann, Induction of tolerance by monoclonal antibody therapy. Nature 320, 449-451 (1986).
10. T. C. Pearson, J. C. Madsen, C. P. Larsen, P. J. Morris, K. J. Wood, Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54, 475-483 (1992).
11. C. P. Larsen, E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, T. C. Pearson, Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434-438 (1996).
12. S. Qin, S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, H. Waldmann, "Infectious" transplantation tolerance. Science 259, 974-977 (1993).
13. S. P. Cobbold, E. Adams, L. Graca, S. Daley, S. Yates, A. Paterson, N. J. Robertson, K. F. Nolan, P. J. Fairchild, H. Waldmann, Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol. Rev. 213, 239-255 (2006).
14. K. M. Plain, J. Chen, S. Merten, X. Y. He, B. M. Hall, Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: Association with TH2 cytokines not anergy. Transplantation 67, 605-613 (1999).
15. L. Chatenoud, E. Thervet, J. Primo, J. F. Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 91, 123-127 (1994).
16. L. Chatenoud, J. Primo, J. F. Bach, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947-2954 (1997).
17. D. Abramowicz, L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, L. De Pauw, J. Wybran, P. Kinnaert, E. Dupont, C. Toussaint, Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47, 606-608 (1989).
18. L. Chatenoud, C. Ferran, C. Legendre, I. Thouard, S. Merite, A. Reuter, Y. Gevaert, H. Kreis, P. Franchimont, J. F. Bach, In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49, 697-702 (1990).
19. L. Chatenoud, M. Jonker, F. Villemain, G. Goldstein, J. F. Bach, The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 232, 1406-1408 (1986).
20. S. Bolt, E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S. D. Gorman, M. Clark, H. Waldmann, The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23, 403-411 (1993).
21. D. Xu, M. L. Alegre, S. S. Varga, A. L. Rothermel, A. M. Collins, V. L. Pulito, L. S. Hanna, K. P. Dolan, P. W. Parren, J. A. Bluestone, L. K. Jolliffe, R. A. Zivin, In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 200, 16-26 (2000).
22. B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, L. Schandene, L. Crenier, C. De Block, J. M. Seigneurin, P. De Pauw, D. Pierard, I. Weets, P. Rebello, P. Bird, E. Berrie, M. Frewin, H. Waldmann, J. F. Bach, D. Pipeleers, L. Chatenoud, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
23. B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Van de Velde, L. Crenier, C. De Block, S. Candon, H. Waldmann, A. G. Ziegler, L. Chatenoud, D. Pipeleers, Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual β cell mass. Diabetologia 53, 614-623 (2010).
24. K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, J. A. Bluestone, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
25. K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, J. A. Bluestone, A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769 (2005).
26. P. E. Rao, G. Olini, J. Kille, E. Muchmore, M. A. Talle, G. Brake, S. A. Rudnick, OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation 52, 691-697 (1991).
27. null mice. J. Exp. Med. 184, 2049-2053 (1996).
28. A. de la Hera, U. Müller, C. Olsson, S. Isaaz, A. Tunnacliffe, Structure of the T cell antigen receptor (TCR): Two CD3ε subunits in a functional TCR/CD3 complex. J. Exp. Med. 173, 7-17 (1991).
29. O. Leo, M. Foo, D. H. Sachs, L. E. Samelson, J. A. Bluestone, Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. U.S.A. 84, 1374-1378 (1987).
30. R. Hirsch, J. A. Bluestone, L. DeNenno, R. E. Gress, Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49, 1117-1123 (1990).
31. L. Chatenoud, CD3-specific antibody-induced active tolerance: From bench to bedside. Nat. Rev. Immunol. 3, 123-132 (2003).
32. R. A. Van Lier, J. H. Boot, E. R. De Groot, L. A. Aarden, Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: Effects of heavy chain isotype in monocyte-dependent systems. Eur. J. Immunol. 17, 1599-1604 (1987).
33. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
34. M. Belghith, J. A. Bluestone, S. Barriot, J. Mégret, J. F. Bach, L. Chatenoud, TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9, 1202-1208 (2003).
35. + T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J. Immunol. 180, 5430-5438 (2008).
36. D. Bresson, L. Togher, E. Rodrigo, Y. Chen, J. A. Bluestone, K. C. Herold, M. von Herrath, Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116, 1371-1381 (2006).
37. J. Nishio, M. Feuerer, J. Wong, D. Mathis, C. Benoist, Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J. Exp. Med. 207, 1879-1889 (2010).
38. S. You, M. Belghith, S. Cobbold, M. A. Alyanakian, C. Gouarin, S. Barriot, C. Garcia, H. Waldmann, J. F. Bach, L. Chatenoud, Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54, 1415-1422 (2005).
39. S. You, N. Thieblemont, M. A. Alyanakian, J. F. Bach, L. Chatenoud, Transforming growth factor-β and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol. Rev. 212, 185-202 (2006).
40. J. B. Prins, J. A. Todd, N. R. Rodrigues, S. Ghosh, P. M. Hogarth, L. S. Wicker, E. Gaffney, P. L. Podolin, P. A. Fischer, A. Sirotina, L. B. Peterson, Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science 260, 695-698 (1993).
41. H. J. Garchon, P. Bedossa, L. Eloy, J. F. Bach, Identification and mapping to chromosome 1 of a susceptibility locus for periinsulitis in non-obese diabetic mice. Nature 353, 260-262 (1991).
42. J. V. Ravetch, J. P. Kinet, Fc receptors. Annu. Rev. Immunol. 9, 457-492 (1991).
43. E. Rogier, A. Durrbach, L. Abecassis, S. Ferlicot, R. Snanoudj, S. Baudreuil, N. Arzouk, A. Vazquez, B. Charpentier, M. F. Bourgeade, A novel biological assay to detect the active form of TGF-β in urine to monitor renal allograft rejection. Kidney Int. 68, 1875-1883 (2005).
44. 2 fragments of 2C11, W. Paul for providing the 11B11 antibody, and C. J. M. Melief for providing the 2G7 antibody. Funding: Supported by grants from the European Community (FP6, Integrated Project: RISET "Reprogramming the Immune System for the establishment of tolerance"), Fondation pour la Recherche Médicale (FRM; Appel d'offre "Immunothérapies"), INSERM, and Fondation Day Solvay. C.K. was supported by a Dr. Karl-Wilder Stiftung fellowship. Production of otelixizumab was in part funded by Tolerx Inc., the licensee and developer of this drug. Author contributions: C.K. and S.Y. participated to designing the study, conducted the experiments, analyzed the data, and contributed to the writing of the paper; F.V. conducted mouse experiments; G.H. provided the otelixizumab antibody and contributed to critical reading of the manuscript; P.v.E. conducted the CD8 ELISPOT assay and contributed to critical reading of the manuscript; H.W. contributed to the analysis of the data and writing of the paper; L.C. and J.-F.B. designed the study, provided funding, analyzed the data, and wrote the paper. Competing interests: G.H. and H.W. are stockholders in Tolerx Inc., the licenser and developer of otelixizumab, are inventors on a patent filed by Oxford University relating to the clinical use of otelixizumab, and have a potential royalty entitlement from the University of Oxford related to commercial development of otelixizumab. The other authors declare that they have no competing interests.